Inhibrx Biosciences Reports Q3 2026 Revenue of $2.0 Million and Net Loss of $38.7 Million

Inhibrx Biosciences reported third-quarter 2026 revenue of $2.0 million and a net loss of $38.7 million, compared with no revenue and a net loss of $35.3 million in the year-earlier quarter. The company had $199.5 million in cash and cash equivalents as of September 30, 2026. Its clinical programs…